Literature DB >> 19694602

Gemfibrozil, stretching arms beyond lipid lowering.

Avik Roy1, Kalipada Pahan.   

Abstract

Gemfibrozil is long known for its ability to reduce the level of triglycerides in the blood circulation and to decrease the risk of hyperlipidemia. However, a number of recent studies reveal that apart from its lipid-lowering effects, gemfibrozil can also regulate many other signaling pathways responsible for inflammation, switching of T-helper cells, cell-to-cell contact, migration, and oxidative stress. In this review, we have made an honest attempt to analyze various biological activities of gemfibrozil and associated mechanisms that may help to consider this drug for different human disorders as primary or adjunct therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694602      PMCID: PMC2772998          DOI: 10.1080/08923970902785253

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  98 in total

1.  Properties of sterol biosynthesis in human leukocytes: effects of gemfibrozil.

Authors:  D J Betteridge; M J Higgins; D J Galton
Journal:  Proc R Soc Med       Date:  1976

2.  Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?

Authors:  Z Balogh; I Seres; M Harangi; P Kovács; G Kakuk; G Paragh
Journal:  Diabetes Metab       Date:  2001-11       Impact factor: 6.041

3.  Specific tropism of HIV-1 for microglial cells in primary human brain cultures.

Authors:  B A Watkins; H H Dorn; W B Kelly; R C Armstrong; B J Potts; F Michaels; C V Kufta; M Dubois-Dalcq
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

4.  Induction of nitric-oxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells.

Authors:  K Pahan; F G Sheikh; X Liu; S Hilger; M McKinney; T M Petro
Journal:  J Biol Chem       Date:  2000-12-07       Impact factor: 5.157

5.  Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.

Authors:  Fabien Forcheron; Ana Cachefo; Sylvie Thevenon; Claudie Pinteur; Michel Beylot
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

Review 6.  Multidrug permeases and subcellular cholesterol transport.

Authors:  Y A Ioannou
Journal:  Nat Rev Mol Cell Biol       Date:  2001-09       Impact factor: 94.444

7.  Immunodepletion experiments suggest that acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines.

Authors:  O Lee; C C Chang; W Lee; T Y Chang
Journal:  J Lipid Res       Date:  1998-08       Impact factor: 5.922

8.  Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages.

Authors:  G Chinetti; S Lestavel; J-C Fruchart; V Clavey; B Staels
Journal:  Circ Res       Date:  2003-02-07       Impact factor: 17.367

Review 9.  Lipid homeostasis in macrophages - implications for atherosclerosis.

Authors:  G Schmitz; M Grandl
Journal:  Rev Physiol Biochem Pharmacol       Date:  2008       Impact factor: 5.545

10.  Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines.

Authors:  Hiroshi Oshio; Takaaki Abe; Tohru Onogawa; Hideo Ohtsuka; Takeaki Sato; Takayuki Ii; Kouji Fukase; Mitsuhisa Muto; Yu Katayose; Masaya Oikawa; Toshiki Rikiyama; Shinichi Egawa; Michiaki Unno
Journal:  J Gastroenterol       Date:  2008-07-23       Impact factor: 7.527

View more
  30 in total

1.  The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice.

Authors:  Akshata Almad; A Todd Lash; Ping Wei; Amy E Lovett-Racke; Dana M McTigue
Journal:  Exp Neurol       Date:  2011-09-21       Impact factor: 5.330

2.  PPARα in lysosomal biogenesis: A perspective.

Authors:  Arunava Ghosh; Kalipada Pahan
Journal:  Pharmacol Res       Date:  2015-11-24       Impact factor: 7.658

3.  Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Arunava Ghosh; Suresh Babu Rangasamy; Khushbu K Modi; Kalipada Pahan
Journal:  J Neurochem       Date:  2017-04-03       Impact factor: 5.372

Review 4.  PPARα Between Aspirin and Plaque Clearance.

Authors:  Sujyoti Chandra; Avik Roy; Dhruv R Patel; Kalipada Pahan
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

5.  Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.

Authors:  Carl G Gottschalk; Malabendu Jana; Avik Roy; Dhruv R Patel; Kalipada Pahan
Journal:  J Neurosci       Date:  2021-01-29       Impact factor: 6.167

6.  Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses.

Authors:  Shringkhala Bajimaya; Tünde Frankl; Tsuyoshi Hayashi; Toru Takimoto
Journal:  Virology       Date:  2017-07-25       Impact factor: 3.616

7.  Activation of peroxisome proliferator-activated receptor α induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders.

Authors:  Arunava Ghosh; Malabendu Jana; Khushbu Modi; Frank J Gonzalez; Katherine B Sims; Elizabeth Berry-Kravis; Kalipada Pahan
Journal:  J Biol Chem       Date:  2015-03-06       Impact factor: 5.157

8.  Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons.

Authors:  Carl G Gottschalk; Avik Roy; Malabendu Jana; Madhuchhanda Kundu; Kalipada Pahan
Journal:  Mol Neurobiol       Date:  2019-05-24       Impact factor: 5.590

9.  Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense.

Authors:  Grant T Corbett; Avik Roy; Kalipada Pahan
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

10.  Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders.

Authors:  Arunava Ghosh; Kalipada Pahan
Journal:  J Biol Chem       Date:  2012-06-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.